title: Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia.
abstract: Recent studies show that redox-active small molecules are selectively cytotoxic to chronic lymphocytic leukemia (CLL). Although elevated levels of reactive oxygen species in CLL cells have been implicated, the molecular mechanism underlying this selectivity is unclear. In other cell types, the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway regulates the oxidative stress response. We found elevated Nrf2 signaling in untreated CLL cells compared with normal lymphocytes. Therefore, we tested 27 known electrophilic and antioxidant compounds with drug-like properties and determined their CLL-selective cytotoxicity and effect on Nrf2 signaling. The selected compounds were from five distinct structural classes; alpha-beta unsaturated carbonyls, isothiocyanates, sulfhydryl reactive metals, flavones, and polyphenols. Our results show that compounds containing alpha-beta unsaturated carbonyls, sulfhydryl reactive metals, and isothiocyanates are strong activators of Nrf2 in a reporter assay system and in primary human CLL based on increased expression of the Nrf2 target heme oxygenase-1. alpha-beta Unsaturated carbonyl-containing compounds were selectively cytotoxic to CLL, and loss of the alpha-beta unsaturation abrogated Nrf2 activity and CLL toxicity. The alpha-beta unsaturated carbonyl containing compounds ethacrynic acid and parthenolide activated Nrf2 in normal peripheral blood mononuclear cells, but had a less potent effect in CLL cells. Furthermore, ethacrynic acid bound directly to the Nrf2-negative regulator Kelch-like ECH-associated protein 1 (Keap1) in CLL cells. These experiments document the presence of Nrf2 signaling in human CLL and suggest that altered Nrf2 responses may contribute to the observed selective cytotoxicity of electrophilic compounds in this disease.
authors.affiliation: Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
authors.forename: Raymond P
authors.initials: RP
authors.lastname: Wu
authors.forename: Tomoko
authors.initials: T
authors.lastname: Hayashi
authors.forename: Howard B
authors.initials: HB
authors.lastname: Cottam
authors.forename: Guangyi
authors.initials: G
authors.lastname: Jin
authors.forename: Shiyin
authors.initials: S
authors.lastname: Yao
authors.forename: Christina C N
authors.initials: CC
authors.lastname: Wu
authors.forename: Michael D
authors.initials: MD
authors.lastname: Rosenbach
authors.forename: Maripat
authors.initials: M
authors.lastname: Corr
authors.forename: Richard B
authors.initials: RB
authors.lastname: Schwab
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Carson
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000737:chemistry; D045744:Cell Line, Tumor; D005419:Flavonoids / Q000737:chemistry; D015973:Gene Expression Regulation, Leukemic; D017930:Genes, Reporter; D051547:Heme Oxygenase-1 / Q000096:biosynthesis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D051267:NF-E2-Related Factor 2 / Q000096:biosynthesis*; D018384:Oxidative Stress; D010636:Phenols / Q000737:chemistry; D016133:Polymerase Chain Reaction; D059808:Polyphenols; D015398:Signal Transduction; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D005419:Flavonoids; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D010636:Phenols; D059808:Polyphenols; D051547:Heme Oxygenase-1